We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACGN
301
PUT
DELISTED
Aceragen Inc
ACGN
$95K ﹤0.01%
2
-11
-85% -$5.05K
OPXAW
302
DELISTED
Opexa Therapeutics, Inc.
OPXAW
$93K ﹤0.01%
+545,505
New +$81.6K
ACGN
303
DELISTED
Aceragen Inc
ACGN
$86K ﹤0.01%
171
-698
-80% -$320K
TLPH icon
304
PUT
Talphera
TLPH
$67.5M
$79K ﹤0.01%
9
-7
-44% -$547
APEN
305
DELISTED
Apollo Endosurgery, Inc.
APEN
$74K ﹤0.01%
3,489
-8,715
-71% -$862K
SEEL
306
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
CYTR
307
PUT
DELISTED
CytRx Corp
CYTR
$64K ﹤0.01%
29
+1
+4% +$25
ALBO
308
PUT
DELISTED
Albireo Pharma Inc
ALBO
$19K ﹤0.01%
6
– –
ITP icon
309
PUT
IT Tech Packaging
ITP
$2.85M
$17K ﹤0.01%
+10
New +$168
BPTH
310
DELISTED
Bio-Path Holdings Inc
BPTH
$16K ﹤0.01%
+3
New +$16.4K
A icon
311
CALL
Agilent Technologies
A
$39.6B
– –
-329
Closed -$1.37M
A icon
312
PUT
Agilent Technologies
A
$39.6B
– –
-540
Closed -$2.24M
ACHC icon
313
CALL
Acadia Healthcare
ACHC
$2.53B
– –
-398
Closed -$1.3M
ACHC icon
314
Acadia Healthcare
ACHC
$2.53B
– –
-9,074
Closed -$296K
ACHC icon
315
PUT
Acadia Healthcare
ACHC
$2.53B
– –
-728
Closed -$2.37M
ADVM
316
CALL
DELISTED
Adverum Biotechnologies
ADVM
– –
-8
Closed -$328K
AGIO icon
317
Agios Pharmaceuticals
AGIO
$2.1B
– –
-3,163
Closed -$341K
ALKS icon
318
CALL
Alkermes
ALKS
$8.13B
– –
-102
Closed -$622K
ALKS icon
319
PUT
Alkermes
ALKS
$8.13B
– –
-485
Closed -$2.96M
ARWR icon
320
CALL
Arrowhead Research
ARWR
$12.2B
– –
-3,053
Closed -$2.06M
ARWR icon
321
Arrowhead Research
ARWR
$12.2B
– –
-74,204
Closed -$502K
ARWR icon
322
PUT
Arrowhead Research
ARWR
$12.2B
– –
-3,598
Closed -$2.43M
AXGN icon
323
Axogen
AXGN
$2.29B
– –
-318,136
Closed -$1.11M
BLRX
324
BioLineRX
BLRX
$12.2M
– –
-1,241
Closed -$1.57M
CASI
325
DELISTED
CASI Pharmaceuticals
CASI
$0 ﹤0.01%
+24,320
New +$364K
11 12
13
14 15

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.